[aerobic capacity decreases]{.smallcaps} by ∼10% every 10 yr after 30 yr of age with the progression of aging ([@B2]). A reduction in O~2~ utilization efficiency in the muscles has been suggested to be one of the mechanisms underlying this decrease in aerobic capacity ([@B14], [@B48]). Experimentally, the mitochondrial electron transport chain (ETC) function, especially complex IV (cytochrome *c* oxidase) activity, was reported to decline with aging in human ([@B32], [@B45], [@B50]) and animal muscles ([@B13], [@B42], [@B49]). The dysfunction of mitochondria has been suggested not only to decrease exercise efficiency ([@B5], [@B10], [@B47]), but also to enhance the generation of reactive oxygen species to injure the tissues ([@B13], [@B42], [@B48], [@B49]), which may evoke chronic inflammatory responses in the body and thereby cause lifestyle-related diseases ([@B18]). Thus the dysfunction of mitochondrial function may be one of the key mechanisms in limiting daily physical activity and evoking lifestyle-related diseases in middle-aged and older people ([@B18], [@B19], [@B40]).

To prevent this, aerobic exercise training above a given intensity has been recommended ([@B1]); however, during exercise, the ATP demand increases drastically in active muscles in the face of the decline in mitochondrial functions with aging ([@B32], [@B45], [@B48], [@B50]). Consequently, there is a huge imbalance between ATP production and demand ([@B23]), which may accelerate lactic acid production in muscles and thus the dissociation of hydrogen ions, evoking panting as compensatory hyperventilation for metabolic acidosis and sometimes causing pain through the muscle receptors ([@B22]). These responses may diminish the enjoyment of, and intrinsic motivation for, physical activity and may prevent middle-aged and older people from performing exercise training. Accordingly, we surmised that, if some nutritional supplements are proved to improve mitochondrial functions, they will help those who feel difficulty in performing exercise training to lower the psychological barrier.

One of the candidates for these supplements is 5-aminolevulinic acid (ALA). ALA is an amino acid that can be found in many foods and is the sole initial material of heme biosynthesis in vivo ([@B15], [@B37], [@B39]). It has been confirmed that ALA is incorporated into cytochromes *a*, *b*, and *c* in the mitochondrial ETC in vitro ([@B37], [@B39]). Indeed, it has been reported that the oral ingestion of ALA by mice increased complex IV activity and raised the ATP production rate in the liver ([@B38]). However, no studies have evaluated how ALA affects the age-related reduction in exercise efficiency and the voluntary achievement of exercise training.

Based on these facts, we hypothesized that, if the oral ingestion of ALA accelerated the O~2~ utilization efficiency in muscle mitochondria, it would increase the exercise efficiency and thereby improve the training achievement in older human subjects. To examine this hypothesis, we conducted a randomized, placebo-controlled, double-blind crossover study in older women.

METHODS {#sec1}
=======

Subjects {#sec1-1}
--------

This study was approved by the Review Board on Human Experiments, Shinshu University School of Medicine, and conformed to the standards set by the Declaration of Helsinki. To minimize the effects of subject selection and the levels of training readiness, the subjects were recruited from the 547 participants in the "Jukunen Taiikudaigaku Project," which is a health promotion program for middle-aged and older people in Matsumoto City, Japan. The participants had performed the interval walking training (IWT) program for more than 12 mo before this study; therefore, they were familiar with the exercise testing procedures used in the present study. Moreover, their exercise efficiency had likely reached the steady state and would thus enable us to detect only the effects of ALA intake on their exercise efficiency without accounting for the acute effects of exercise training.

After the experimental protocol was fully explained, 10 healthy older female volunteers (60-69 yr old) gave written, informed consent before participating in this study. Each subject gave a complete medical history and underwent examinations of physical characteristics, resting blood pressure (BP), and peak aerobic capacity (V̇[o]{.smallcaps}~2\ peak~). All subjects were nonsmokers and had no overt history of hepatic, thyroid, renal, metabolic, cardiovascular, or pulmonary disease, or orthopedic limitations in the exercise tests. Moreover, no subjects showed symptoms of iron deficiency anemia, as confirmed in the health examination before participating in the study. In the examination, the hemoglobin concentration (\[Hb\]), mean corpuscular volume, and mean corpuscular \[Hb\] were 14.1 ± 0.7 g/dl (mean ± SD), 90.5 ± 2.2 fl, and 33.8 ± 0.7 g/dl, respectively. Their physical characteristics were similar to those observed in our laboratory\'s previous study ([@B34]) and are summarized in [Table 1](#T1){ref-type="table"}.

###### 

Physical characteristics of subjects

                                               CNT          ALA+SFC                   
  -------------------------------------------- ------------ ------------ ------------ --------------------------------------------
  Age, yr                                      65 ± 3       NA           NA           NA
  Height, cm                                   153 ± 3      NA           NA           NA
  Body weight, kg                              52.6 ± 2.2   52.6 ± 2.1   52.8 ± 2.1   52.8 ± 2.1
  BMI, kg/m^2^                                 22.5 ± 1.0   22.5 ± 1.0   22.6 ± 1.0   22.6 ± 1.0
  HR~rest~, beats/min                          64 ± 2       64 ± 2       62 ± 2       62 ± 2
  SBP~rest~, mmHg                              143 ± 5      135 ± 7      141 ± 6      137 ± 5
  DBP~rest~, mmHg                              82 ± 3       79 ± 4       82 ± 4       79 ± 3
  V̇[o]{.smallcaps}~2peak~, ml·kg^−1^·min^−1^   25.0 ± 1.2   24.7 ± 1.1   25.4 ± 1.6   24.9 ± 1.5
  HR~peak~, beats/min                          150 ± 2      150 ± 2      148 ± 4      149 ± 2
  WL~peak~, W                                  96 ± 5       96 ± 6       93 ± 4       98 ± 3
  Time~exhaustion~, min                        16.7 ± 0.6   16.4 ± 0.7   16.0 ± 0.7   16.8 ± 0.5[\*](#T1F1){ref-type="table-fn"}

Values are means ± SD for age and height, and means ± SE for the other variables; *n* = 10 subjects.

CNT, placebo intake condition; ALA+SFC, 5-aminolevulinic acid + sodium ferrous citrate intake condition; NA, not applicable; BMI, body mass index; HR~rest~, resting heart rate; SBP~rest~ and DBP~rest~, resting systolic and diastolic blood pressure, respectively; V̇[o]{.smallcaps}~2peak~, peak oxygen consumption rate during the graded cycling test; HR~peak~, peak heart rate at V̇[o]{.smallcaps}~2peak~; WL~peak~, peak workload at V̇[o]{.smallcaps}~2peak~; Time~exhaustion~, exercise time to exhaustion.

Compared with before supplement intake, *P* \< 0.05.

Protocol {#sec1-2}
--------

As shown in [Fig. 1](#F1){ref-type="fig"}, this study was carried out in a randomized, placebo-controlled, double-blind crossover design. All subjects participated in two trials for 9 days each: 7 days of supplement intake, and 2 days of graded cycling tests, with a 14-day washout period between the trials. Subjects ingested either ALA \[ALA + sodium ferrous citrate (SFC) trial, see below for details of SFC\] or placebo supplement (CNT trial) two times per day for 7 days (*days 1--7*). Before and after the supplement intake period (*days 0* and *8*), subjects underwent a graded cycling test, during which the cardiorespiratory responses and lactate concentration in plasma (\[Lac^−^\]~p~) were measured. During the supplement intake period (*days 1--6*), except for the day before the graded cycling test (*day 7*), the training days, intensity, and time were recorded with a triaxial accelerometer (JD Mate; Kissei Comtec, Matsumoto, Japan) ([@B30], [@B34], [@B52]). The reason for no measurement on the 7th day was that we instructed subjects not to perform IWT on that day to avoid any effects of IWT on the results of the graded cycling test scheduled the next day.

![Experimental protocol. Ex, graded cycling exercise test; IWT, interval walking training. The study was conducted using a randomized, placebo-controlled, double-blind crossover design. In each supplement intake, subjects ingested 250 mg of either 5-aminolevulinic acid (ALA) + sodium ferrous citrate (SFC) or placebo supplement (250 mg × 2 = 500 mg/day). See [Table 2](#T2){ref-type="table"} for details of the supplement compositions.](zdg0011616690001){#F1}

Supplements {#sec1-3}
-----------

The composition of supplements (SBI ALApromo, Tokyo, Japan) is shown in [Table 2](#T2){ref-type="table"}. Subjects ingested the supplements more than 1 h before breakfast and dinner for 7 days. The dose of ALA phosphate in the present study (100 mg/day) was higher than the doses used in previous studies (5--50 mg/day) that have examined the effects and safety of ALA supplementation in humans ([@B21], [@B43], [@B51]); however, those studies were performed on relatively sedentary subjects, whereas in the present study we examined the effects of ALA supplementation on exercise efficiency and training achievement when oxygen consumption rate (V̇[o]{.smallcaps}~2~) was increased. Therefore, we thought that a higher dose would be needed to improve mitochondrial function, if it occurred. Regarding dose safety, there is no legal dose limit in Japan because ALA phosphate has been approved as a food ingredient by the Pharmaceutical and Food Safety Bureau, the Ministry of Health, Labour and Welfare. Additionally, because the present study had a placebo-controlled crossover design, we could not test several doses of ALA+SFC.

###### 

Composition of supplements

                                Placebo Supplement (250.00 mg/dose)   ALA+SFC Supplement (250.00 mg/dose)
  ----------------------------- ------------------------------------- -------------------------------------
  ALA phosphate, mg             0.00                                  50.00
  SFC, mg                       0.00                                  57.36
  Pregelatinized starch, mg     247.50                                140.14
  Silicon dioxide mixture, mg   2.50                                  2.50

SFC, as a source of the iron ion, was contained in the supplements to enhance the final step of heme biosynthesis by ABCB6 transporter and ferrochelatase in mitochondria and to prevent the accumulation of heme biosynthesis intermediates, such as protoporphyrin IX, which might cause photodamage to the skin during outdoor exercise ([@B39]). Although SFC is used for anemia treatment in Japan, the dose used in the present study (12 mg iron/day) was much less than that used in regular treatment (100--200 mg iron/day), such that no significant effects on red blood cell production were expected during the 7-day intake period in healthy volunteers.

Dietary Intake {#sec1-4}
--------------

Subjects in both conditions were instructed to maintain their dietary habits, except for the supplements, during the study period. Furthermore, they were instructed to report the food that they consumed during the 7-day supplement intake period in both trials by answering a questionnaire that was prepared by a dietician (FFQg version 3.5; Kenpakusya, Tokyo, Japan). The results are shown in [Table 3](#T3){ref-type="table"}. We confirmed that there were no significant differences in the values between the CNT and ALA+SFC trials (*P* \> 0.2). Moreover, the values generally met the recommended dietary allowance (RDA) for Japanese active older women ([@B29]), and the amount of ALA contained in the diet, as calculated according to the references ([@B15]), was very low compared with that contained in the ALA supplement ([Table 2](#T2){ref-type="table"}).

###### 

Total energy, protein, fat, carbohydrate, ALA, and iron intake per day during the supplement intake period

                    CNT          ALA+SFC
  ----------------- ------------ ------------
  Energy, kcal      1,629 ± 71   1,530 ± 75
  Protein, g        59.7 ± 2.9   58.0 ± 3.7
  Fat, g            48.7 ± 3.6   45.3 ± 2.6
  Carbohydrate, g   232 ± 10     218 ± 11
  ALA, μg           52.9 ± 4.3   53.3 ± 5.0
  Iron, mg          6.5 ± 0.4    6.3 ± 0.5

Values are means ± SE; *n* = 10 subjects.

On the day before the graded cycling test, which occurred four times \[(before and after the ALA or placebo intake periods)/subject × 10 subjects = 40 times, food was controlled over the course of the day (i.e., standardized breakfast, lunch, and dinner)\]: the total calories was 1,816 ± 16 kcal, the total protein was 66.6 ± 0.3 g, the total fat was 33.3 ± 0.1 g, and the total carbohydrate was 307 ± 4 g, with no significant differences observed before and after the supplement intake periods or between the CNT and ALA+SFC trials (*P* \> 0.4). Subjects were asked to eat the standardized breakfast and lunch at normal time and to finish the standardized dinner by 2100. Additionally, subjects were asked to refrain from ingesting alcohol and caffeine during the day.

Graded Cycling Test {#sec1-5}
-------------------

On the day of testing, subjects reported to the laboratory at 0900; they were normally hydrated but had not eaten any food for more than 12 h before the experiment. To ensure that they were well hydrated, they were instructed to drink 500 ml of tap water 2 h before the visit. Furthermore, they were instructed to ingest a supplement 2 h before the visit on *day 8* only. After emptying their bladders, they were weighed in the nude, put on light clothes and shoes, and entered an artificial climate chamber adjusted to 27.0 ± 0.1°C (mean ± range) atmospheric temperature and 50 ± 1% relative humidity. An 18-gauge Teflon catheter was then placed in the left antecubital vein for blood sampling. The catheter was connected to a 20-ml syringe that contained heparinized saline solution through an extension tube 2.0 ml in volume with a three-way stopcock.

Subjects rested quietly in a semirecumbent position in the contoured chair of the cycle ergometer for 60 min, while all of the measurement devices were applied. After resting baseline measurement was taken for 10 min, subjects performed the graded cycling exercise at 60 revolutions/min. After exercising at 0 W and 15 W for 3 min each, the intensity was increased by 15 W every 2 min until they could not maintain the rhythm due to exhaustion. We measured the respiratory gas fraction and ventilation volume (V̇[e]{.smallcaps}) every 15 s (Aeromonitor AE260; Minato, Tokyo, Japan) to determine the V̇[o]{.smallcaps}~2~ and carbon dioxide production rate (V̇[co]{.smallcaps}~2~) ([Fig. 2](#F2){ref-type="fig"}, [Table 4](#T4){ref-type="table"}). In addition, we measured the heart rate (HR) using an electrocardiogram trace (Life Scope 8; Nihon Kohden, Tokyo) and systolic and diastolic BP from the right upper arm at the heart level by inflation of the cuff with sonometric pickup of Korotkoff\'s sound (STBP-780; Colin, Komaki, Japan) every minute.

![Oxygen consumption rate (V̇[o]{.smallcaps}~2~), carbon dioxide production rate (V̇[co]{.smallcaps}~2~), and ventilation volume (V̇[e]{.smallcaps}) responses during graded cycling exercise under placebo (CNT; *left*) and ALA+SFC supplement intake (*right*) conditions. The average value per minute is presented from rest to the highest workload of 75 W at which all subjects could maintain the rhythm. Open symbols, before supplement intake; solid symbols, after supplement intake. Values are means ± SE of 10 subjects. \**P* \< 0.05, \*\**P* \< 0.01, and \*\*\**P* \< 0.001 vs. before supplement intake.](zdg0011616690002){#F2}

###### 

Changes in V̇[o]{.smallcaps}~2~, V̇[co]{.smallcaps}~2~, V̇[e]{.smallcaps}, and \[Lac^−^\]~p~ during the graded cycling test after supplement intake

                                            CNT             ALA+SFC                           
  ----------------------------------------- -------------- --------- -------------- --------- -------
  V̇[o]{.smallcaps}~2~, ml·kg^−1^·min^−1^    −0.17 ± 0.24      NS     −1.01 ± 0.17   \<0.001   0.023
  V̇[co]{.smallcaps}~2~, ml·kg^−1^·min^−1^   −0.19 ± 0.16      NS     −0.79 ± 0.17   0.001     0.036
  V̇[e]{.smallcaps}, ml·kg^−1^·min^−1^       −4.8 ± 6.8        NS     −26.2 ± 9.5    0.022     NS
  \[Lac^−^\]~p~, mmol/l                     −0.04 ± 0.07      NS     −0.23 ± 0.04   \<0.001   0.028

Values are means ± SE; *n* = 10 subjects. Average values during the graded cycling test are presented.

V̇[o]{.smallcaps}~2~, oxygen consumption rate; V̇[co]{.smallcaps}~2~, carbon dioxide production rate; V̇[e]{.smallcaps}, ventilation volume; \[Lac^−^\]~p~, lactate concentration in plasma.

Before vs. after supplement intake.

### V̇[o]{.smallcaps}~2\ peak~ and gas exchange threshold. {#sec1-5-1}

The criteria used to determine V̇[o]{.smallcaps}~2\ peak~ were a respiratory exchange ratio of \>1.1, V̇[o]{.smallcaps}~2~ leveling off, despite increasing exercise intensity, and HR reaching the age-predicted maximal value. V̇[o]{.smallcaps}~2\ peak~ was determined by averaging the three largest consecutive values at the end of exercise. We also determined the gas exchange threshold during graded cycling according to the standard method ([@B3]) from the V̇[o]{.smallcaps}~2~ vs. V̇[co]{.smallcaps}~2~ relationship. Peak HR was adopted at V̇[o]{.smallcaps}~2\ peak~. Because the highest workload at which all subjects could maintain the rhythm for \>1 min in the four graded cycling tests was 75 W, data were presented from rest to 75 W.

### \[Lac^−^\]~p~. {#sec1-5-2}

Blood samples were taken at rest and at the last minute of each intensity to determine \[Lac^−^\]~p~. An aliquot of the blood sample was transferred to a heparin-treated tube and centrifuged for 3 min at 8,000 rpm, and the separated plasma was stored at −85°C until the assays were performed. The plasma was used to determine \[Lac^−^\]~p~ (YSI 2300 Stat Plus; Yellow Springs, OH) ([Fig. 3](#F3){ref-type="fig"}). Additionally, an aliquot of the blood sample at rest was transferred to a heparin-treated tube that was also used to determine \[Hb\] with the sodium lauryl sulfate hemoglobin method.

![Plasma lactate concentration (\[Lac^−^\]~p~) responses during graded cycling exercise under CNT (*left*) and ALA+SFC (*right*) conditions. Open symbols, before supplement intake; solid symbols, after supplement intake. Values are means ± SE of 10 subjects. \*\*\**P* \< 0.001 vs. before supplement intake.](zdg0011616690003){#F3}

### Exercise efficiency. {#sec1-5-3}

V̇[o]{.smallcaps}~2~ and respiratory exchange ratio values during the last minute of each workload were averaged and used to calculate energy expenditure at a given workload. Under these conditions, efficiency was calculated based on the steady-state assumption that energy requirements are met by V̇[o]{.smallcaps}~2~ ([@B6]). In the present study, this was confirmed by the following observations: *1*) V̇[o]{.smallcaps}~2~ during the last minute of each workload was relatively constant; and *2*) when the values were plotted against workload, there was a linear relationship between them in each subject of each condition (all, *R*^2^ \> 0.92, *P* \< 0.009). Efficiency was then determined ([Fig. 4](#F4){ref-type="fig"}) using the method reported by Gaesser and Brooks ([@B16]) with the following equations: gross efficiency = work accomplished/energy expended; net efficiency = work accomplished/energy expended above that at rest; delta efficiency = change in work accomplished/change in energy expended during graded exercise.

![Gross, net, and delta efficiencies during graded cycling exercise under CNT (*left*) and ALA+SFC (*right*) conditions. Open symbols, before supplement intake; solid symbols, after supplement intake. Values are means ± SE of 10 subjects. \**P* \< 0.05 and \*\**P* \< 0.01 vs. before supplement intake.](zdg0011616690004){#F4}

### V̇[o]{.smallcaps}~2~ kinetics. {#sec1-5-4}

V̇[o]{.smallcaps}~2~ measurements every 15 s were used to analyze the transient changes in V̇[o]{.smallcaps}~2~ at the onset of exercise using the method reported by Rossiter et al. ([@B46]) with the following equation: $$\overset{․}{\text{V}}\text{O}_{\text{2}}\left( t \right) = \overset{․}{\text{V}}\text{O}_{\text{2}\,\text{BSLN}} + \Delta\overset{․}{\text{V}}\text{O}_{\text{2}}\left\lbrack {1 - e^{- {({t - {\text{TD}/\tau}})}}} \right\rbrack$$ where the onset of exercise is defined as *t* = 0; V̇[o]{.smallcaps}~2~ (*t*) represents V̇[o]{.smallcaps}~2~ at any time (*t*); V̇[o]{.smallcaps}~2\ BSLN~ is the baseline V̇[o]{.smallcaps}~2~ calculated as an average over 5 min before the onset of exercise; ΔV̇[o]{.smallcaps}~2~ is the steady-state increase in V̇[o]{.smallcaps}~2~ above the baseline V̇[o]{.smallcaps}~2~; *τ* represents the time constant defined as the time required to attain 63% of the ΔV̇[o]{.smallcaps}~2~; and TD represents the mathematically determined time delay for V̇[o]{.smallcaps}~2~ to start to increase after the onset of exercise. Briefly, after abandoning the phase I response of V̇[o]{.smallcaps}~2~ for the first 15 s to exclude the cardiodynamic effect ([@B46]), we determined ΔV̇[o]{.smallcaps}~2~, *τ*, and TD by fitting the V̇[o]{.smallcaps}~2~ data from 15 s to 180 s into the equation so that the sum of the *y* deviation from the equation was minimal ([Table 5](#T5){ref-type="table"}). We performed the analysis only on the transient V̇[o]{.smallcaps}~2~ response from rest to exercise at 0 W, because more than 5-min baseline measurements before increasing workload were reportedly required to determine the parameters ([@B4], [@B11], [@B17], [@B33]).

###### 

V̇[o]{.smallcaps}~2~ kinetics parameters at the onset of cycling exercise

                                                    CNT         ALA+SFC                 
  ------------------------------------------------- ----------- ----------- ----------- ------------------------------------------
  Baseline V̇[o]{.smallcaps}~2~, ml·kg^−1^·min^−1^   3.0 ± 0.2   3.1 ± 0.1   3.1 ± 0.2   2.7 ± 0.2
  ΔV̇[o]{.smallcaps}~2~, ml·kg^−1^·min^−1^           4.5 ± 0.3   4.0 ± 0.2   5.1 ± 0.4   3.6 ± 0.2[†](#T5F2){ref-type="table-fn"}
  *τ*, s                                            43 ± 4      42 ± 5      43 ± 4      30 ± 4[\*](#T5F1){ref-type="table-fn"}
  TD, s                                             3 ± 2       6 ± 3       4 ± 2       3 ± 2

Values are means ± SE; *n* = 10 subjects.

ΔV̇[o]{.smallcaps}~2~, the steady-state increase in V̇[o]{.smallcaps}~2~ above the baseline; *τ*, time constant; TD, time delay.

Compared with before supplement intake:

*P* \< 0.05 and

*P* \< 0.01.

Training Achievement during the Supplement Intake Period {#sec1-6}
--------------------------------------------------------

During the supplement intake period, except for the day before the graded cycling test (*days 1--6*), subjects were instructed to perform IWT, repeating five or more sets of 3 min of low-intensity walking at 40% of V̇[o]{.smallcaps}~2\ peak~, followed by 3 min of high-intensity walking above 70% of V̇[o]{.smallcaps}~2\ peak~ per day for 4 or more days/wk, where training days, intensity, and time were recorded with a portable triaxial accelerometer (JD Mate) and transferred to the computer server at Shinshu University Graduate School of Medicine over the internet ([@B36]). Training intensity was calculated from the product of body weight and the average norm of three-dimensional accelerations per minute and presented as accumulated training impulse (N·min) ([@B24], [@B52]) for 6 days ([Fig. 5](#F5){ref-type="fig"}) and for each day ([Fig. 6](#F6){ref-type="fig"}). Because we failed to record part of the training achievement in 1 of the 10 subjects, training data were presented for the rest of the 9 subjects whose achievements were successfully recorded throughout the intervention.

![Training days (*A*), training impulse (*B*), and training time (*C*) at total, fast, and slow walking during the supplement intake period. Values are means ± SE of 9 subjects. \**P* \< 0.05 and \*\*\**P* \< 0.001 between the CNT and ALA+SFC trials.](zdg0011616690005){#F5}

![Ratio of subjects performing training to total subjects (*A*), training impulse (*B*), and training time (*C*) at fast walking on each day in the period of supplement intake. Values are means ± SE of 9 subjects. \**P* \<0.05 compared with the CNT trial.](zdg0011616690006){#F6}

Regarding the weather conditions on the first 6 of 7 days of supplement intake in the CNT and ALA+SFC trials, the precipitation from 0500 to 2000 was 1.7 ± 0.7 and 2.6 ± 0.8 mm/day, atmospheric temperature was 15.7 ± 1.1 and 13.9 ± 1.0°C, and relative humidity was 71 ± 1 and 75 ± 1%, respectively, with no significant differences observed between trials (all, *P* \> 0.1), which suggests no effects of weather conditions on the training achievement.

Statistics {#sec1-7}
----------

One-way ANOVA for repeated measures was used to examine any significant differences in physical characteristics and V̇[o]{.smallcaps}~2~ kinetics parameters before vs. after the supplement intake period ([Tables 1](#T1){ref-type="table"} and [5](#T5){ref-type="table"}) and to examine dietary intake in the supplement intake period between trials ([Table 3](#T3){ref-type="table"}). This model was also used to examine any significant differences in training days, training impulse, and training time during the supplement intake period ([Fig. 5](#F5){ref-type="fig"}). Two-way ANOVA for repeated measures was used to examine any significant differences in variables during the graded cycling test before vs. after the supplement intake period in each trial ([Figs. 2](#F2){ref-type="fig"}--[4](#F4){ref-type="fig"}) and their changes after the period of supplement intake between trials ([Table 4](#T4){ref-type="table"}). This model was also used to examine any significant differences in training impulse ([Fig. 6*B*](#F6){ref-type="fig"}) and time ([Fig. 6*C*](#F6){ref-type="fig"}) at fast walking and in the weather conditions during the supplement intake period between trials. As a subsequent post hoc test, the Tukey-Kramer test was used to perform any pairwise comparisons between trials. The sign test was used to examine any significant differences in the %ratio of the number of subjects performing walking training to the total number of subjects on each day in the period of supplement intake between trials ([Fig. 6*A*](#F6){ref-type="fig"}), where the data from the CNT and ALA+SFC trials were paired in each subject.

In addition, because this study was conducted in a two-period crossover design, the changes in respiratory responses to graded cycling were further analyzed to test three effects: carryover (physiological and other effects of the first supplement period are still present when the subject enters the second supplement period), period \[the effect of stimulation order was present in CNT-(ALA+SFC) sequence group vs. (ALA+SFC)-CNT sequence group\], and supplement effects. For the analysis, data were averaged during the graded cycling test, and changes after supplement intake (after-before) were calculated for each period. The three effects were then determined by the method reported by Chow and Liu ([@B8]). The null hypothesis was rejected when *P* \< 0.05. Values are expressed as means ± SE, unless otherwise indicated.

RESULTS {#sec2}
=======

As shown in [Table 1](#T1){ref-type="table"}, body weight, body mass index, HR, and BP at rest remained unchanged after supplement intake in both trials (all, *P* \> 0.1). \[Hb\] before and after supplement intake was 13.3 ± 0.3 and 13.1 ± 0.3 g/dl in the CNT trial, respectively, and 13.1 ± 0.4 and 12.9 ± 0.4 g/dl in the ALA+SFC trial, respectively, with no significant differences between them (all, *P* \> 0.1). Additionally, V̇[o]{.smallcaps}~2\ peak~ and peak HR during the graded cycling test remained unchanged after supplement intake in both trials (both, *P* \> 0.3); however, the peak workload tended to increase (*P* = 0.081). Furthermore, the time to exhaustion significantly increased by 0.8 min in the ALA+SFC trial (*P* = 0.022), although not in the CNT trial (*P* = 0.47) ([Table 1](#T1){ref-type="table"}); the increase in the time to exhaustion was significantly greater in the ALA+SFC than in the CNT trial (*P* = 0.040).

[Figure 2](#F2){ref-type="fig"} shows the V̇[o]{.smallcaps}~2~, V̇[co]{.smallcaps}~2~, and V̇[e]{.smallcaps} responses during the graded cycling test. When comparing the responses obtained before and after supplement intake, an increase in V̇[o]{.smallcaps}~2~ after supplement intake was significantly attenuated by 12% for every workload 1 min after the start of exercise in the ALA+SFC trial (*P* \< 0.001), although this did not occur in the CNT trial (*P* = 0.49). Similarly, an increase in V̇[co]{.smallcaps}~2~ and V̇[e]{.smallcaps} was significantly attenuated by 11% for every workload 2 min after the start of exercise in the ALA+SFC trial (*P* = 0.001 for V̇[co]{.smallcaps}~2~, *P* = 0.022 for V̇[e]{.smallcaps}), although this did not occur in the CNT trial (*P* = 0.28 for V̇[co]{.smallcaps}~2~, *P* = 0.50 for V̇[e]{.smallcaps}). We confirmed that the reduction in V̇[o]{.smallcaps}~2~ and V̇[co]{.smallcaps}~2~ after supplement intake was significantly greater in the ALA+SFC than in the CNT trial ([Table 4](#T4){ref-type="table"}), but the reduction in V̇[e]{.smallcaps} was not different between the trials. The gas exchange threshold before and after supplement intake was 15.2 ± 0.8 and 15.0 ± 0.9 ml·kg^−1^·min^−1^ in the CNT trial, respectively, and 15.9 ± 1.1 and 15.7 ± 0.9 ml·kg^−1^·min^−1^ in the ALA+SFC trial, respectively, with no significant differences between them (all, *P* \> 0.4). In addition, there were no significant differences in HR and BP during the graded cycling test before and after supplement intake in either trial (all, *P* \> 0.05).

[Figure 3](#F3){ref-type="fig"} shows \[Lac^−^\]~p~ during the graded cycling test. After supplement intake, the increase in \[Lac^−^\]~p~ was significantly attenuated by 16% every workload in the ALA+SFC trial (*P* \< 0.001), although this did not occur in the CNT trial (*P* = 0.59). We confirmed that the reduction in \[Lac^−^\]~p~ after supplement intake was significantly greater in the ALA+SFC than in the CNT trial ([Table 4](#T4){ref-type="table"}).

The changes in respiratory responses to the graded cycling test were also examined by comparing the CNT-(ALA+SFC) sequence group (*n* = 5) vs. the (ALA+SFC)-CNT sequence group (*n* = 5) ([@B8], [@B26]). For the CNT-(ALA+SFC) sequence, the change in V̇[o]{.smallcaps}~2~ after supplement intake was −0.02 ± 0.20 ml·kg^−1^·min^−1^ in *period 1* and −0.96 ± 0.25 ml·kg^−1^·min^−1^ in *period 2*, and the difference over time (*periods 1−2*) was 0.93 ± 0.32 ml·kg^−1^·min^−1^. For the (ALA+SFC)-CNT sequence, the change in V̇[o]{.smallcaps}~2~ after supplement intake was −1.06 ± 0.26 ml·kg^−1^·min^−1^ in *period 1* and −0.32 ± 0.45 ml·kg^−1^·min^−1^ in *period 2*, and the difference over time (*periods 1−2*) was −0.74 ± 0.56 ml·kg^−1^·min^−1^, which was significantly different from that observed in the CNT-(ALA+SFC) sequence (*P* = 0.032), thus indicating a significant supplement effect. Similarly, a significant supplement effect was observed in V̇[co]{.smallcaps}~2~ (*P* = 0.048) and \[Lac^−^\]~p~ (*P* = 0.039), but was not observed in V̇[e]{.smallcaps} (*P* = 0.13). No carryover or period effects were observed in V̇[o]{.smallcaps}~2~, V̇[co]{.smallcaps}~2~, V̇[e]{.smallcaps}, or \[Lac^−^\]~p~ (*P* = 0.52--0.97).

[Figure 4](#F4){ref-type="fig"} shows gross, net, and delta efficiencies during the graded cycling test. When comparing the responses obtained before and after supplement intake, gross and net efficiencies after supplement intake were significantly increased by 12% for every workload in the ALA+SFC trial (*P* = 0.0086 for gross efficiency, *P* = 0.039 for net efficiency), although this did not occur in the CNT trial (*P* = 0.52 for gross efficiency, *P* = 0.34 for net efficiency). On the other hand, we found no significant differences in delta efficiency before vs. after supplement intake in the ALA+SFC trial (*P* = 0.61).

To assess the effect of ALA on transient V̇[o]{.smallcaps}~2~ responses to exercise, we determined the V̇[o]{.smallcaps}~2~ kinetics parameters at the onset of exercise. As shown in [Table 5](#T5){ref-type="table"}, we found that *τ* after supplement intake was significantly shortened (*P* = 0.026), and that ΔV̇[o]{.smallcaps}~2~ was significantly decreased (*P* = 0.0018) in the ALA+SFC trial, although this did not occur in the CNT trial (both, *P* \> 0.2), whereas TD remained unchanged after supplement intake in both trials (both, *P* \> 0.1).

[Figure 5](#F5){ref-type="fig"} shows training days (*A*), training impulse (*B*), and training time (*C*) during the supplement intake period (*days 1--6*). Training days were 42% higher in the ALA+SFC than the CNT trial (*P* = 0.028). The impulses at total and fast walking were 72% and 102% higher in the ALA+SFC than the CNT trial (*P* \< 0.001 and *P* = 0.027, respectively). The training time at fast walking was 69% higher in the ALA+SFC than the CNT trial (*P* = 0.039).

[Figure 6](#F6){ref-type="fig"} shows %ratio of the number of subjects performing training to that of total subjects (*A*), training impulse (*B*), and training time (*C*) on each day in the period of supplement intake. The ratio in the ALA+SFC trial tended to increase after the 5th and 6th days, but with no significant differences from that in the CNT trial (*P* = 0.29 and *P* = 0.22, respectively). Training impulse at fast walking in the ALA+SFC trial increased after the 3rd day, with significant differences from that in the CNT trial (*P* = 0.028). Similarly, training time at fast walking in the ALA+SFC trial increased after the 3rd day, with significant differences from that in the CNT trial (*P* = 0.039).

DISCUSSION {#sec3}
==========

Although ALA has been reported to enhance the production of heme and cytochromes in vitro ([@B37], [@B39]) to activate complex IV and to increase the ATP production rate in mice ([@B38]), there have been no studies conducted to evaluate the effects of ALA on exercise efficiency and home-based walking training achievement in older human subjects. In the present study, we first found in older women that the increases in V̇[o]{.smallcaps}~2~, V̇[co]{.smallcaps}~2~, and \[Lac^−^\]~p~ during the graded cycling test were significantly reduced at every workload with ALA+SFC supplementation, and that all of the reductions were significantly greater in the ALA+SFC trial than in the CNT trial. In addition, training days, training impulse, and training time at fast walking were significantly higher in the ALA+SFC trial than in the CNT trial.

V̇[o]{.smallcaps}~2~ during the Graded Cycling Test {#sec3-1}
--------------------------------------------------

As shown in [Figs. 2](#F2){ref-type="fig"} and [4](#F4){ref-type="fig"}, the increase in V̇[o]{.smallcaps}~2~ during the graded cycling test was significantly reduced by 12% at every workload in the ALA+SFC trial, but not in the CNT trial, with 12% increases in gross and net efficiencies with significance. Regarding the mechanisms, Ferguson et al. ([@B13]) suggested that, in *Drosophila melanogaster*, the activity of complex IV, which is one of the enzymes in the mitochondrial ETC, decreased in an older body such that the reduced transferring rate of electrons caused a backlog of electrons in the system, increased the reactive oxygen species generation rate, and decreased the ATP production rate. In fact, biochemical studies in human skeletal muscle suggested that the activity of complex IV decreased from 20 to 80 yr old by 35--50% ([@B45], [@B50]). Additionally, a histochemical study suggested that complex IV-deficient fibers increased with age and were observed in ∼80% of human skeletal muscles at age 80 yr ([@B32]). These results suggest that complex IV activity decreases with advanced aging and results in the decreased efficiency of utilizing O~2~ to produce ATP.

Recently, Sacchetti et al. ([@B47]) examined the influence of age on cycling efficiency and reported that the gross efficiency was lower in older than young men, regardless of cadence and power output, and it was 13% lower at 60 revolutions/min. Similarly, Bell et al. ([@B5]) reported that the net efficiency during cycling was 16% lower at 60 revolutions/min in older than in younger physically active women. Furthermore, Conley et al. ([@B10]) examined the factors affecting the reduced cycling efficiency (work/V̇[o]{.smallcaps}~2~) with age and suggested that the phosphorylative-coupling efficiency (ATP/V̇[o]{.smallcaps}~2~) rather than contractile-coupling efficiency (work/ATP) played a key role in the reduced cycling efficiency with age. In the present study, we first confirmed in the whole body of older human subjects that the oral ingestion of ALA increased the gross and net efficiencies during cycling by 12% at the cadence mentioned above; however, we found no significant increase in delta efficiency, reflecting in part the phosphorylative-coupling efficiency, in the ALA+SFC trial ([Fig. 4](#F4){ref-type="fig"}).

The result of no significant increase in delta efficiency in the ALA+SFC trial might be due to the requirement to determine the value at which V̇[o]{.smallcaps}~2~ reached a "steady state" after an increase in workload. If ALA accelerates the O~2~ utilization rate transitionally at an increase in workload, it would not be detected by the steady-state method. We, therefore, analyzed V̇[o]{.smallcaps}~2~ kinetics at the onset of exercise and found that *τ* significantly decreased in the ALA+SFC trial, but did not decrease in the CNT trial ([Table 5](#T5){ref-type="table"}), suggesting that ALA accelerated the O~2~ utilization rate. Additionally, we found that ΔV̇[o]{.smallcaps}~2~ significantly decreased in the ALA+SFC trial. Because the product of (*τ* + TD) and ΔV̇[o]{.smallcaps}~2~ is an indicator of an O~2~ deficit ([@B4], [@B46]), the decrease is consistent with the attenuated increase in \[Lac^−^\]~p~ in the ALA+SFC trial, as described below ([Fig. 3](#F3){ref-type="fig"}). These results suggest that ALA accelerates the O~2~ utilization rate to facilitate aerobic ATP production at the onset of exercise.

We analyzed V̇[o]{.smallcaps}~2~ kinetics only during a rest-to-work transition using the method reported by Rossiter et al. ([@B46]), which is commonly used during a work-to-work transition ([@B17], [@B33]), due to insufficient time for baseline measurements before implementing stepwise increases in workload. However, we found that the difference in the increase in \[Lac^−^\]~p~ during graded exercise before vs. after supplement intake was enlarged as the workload increased, suggesting that the O~2~ deficit would also decrease at the subsequent stepwise increases of workload in the ALA+SFC trial.

Regarding the relationship between V̇[o]{.smallcaps}~2~ kinetics and mitochondrial functions, it has been reported that V̇[o]{.smallcaps}~2~ kinetics slow down with aging ([@B17], [@B33]), whereas it is accelerated with improvements in mitochondrial functions after exercise training ([@B4], [@B11]). Additionally, the acceleration of V̇[o]{.smallcaps}~2~ kinetics has been suggested to be due to an improved O~2~ utilization rate by the muscle ([@B4], [@B17], [@B33]). These results suggest that dietary supplementation of ALA improved mitochondrial functions to recover the age-associated decrease in transient O~2~ utilization rates, as well as exercise efficiency determined as work per the total metabolic cost of exercise.

\[Lac^−^\]~p~ during the Graded Cycling Test {#sec3-2}
--------------------------------------------

As mentioned above, an increase in \[Lac^−^\]~p~ during the graded cycling test was significantly reduced by 16% at every workload in the ALA+SFC trial ([Fig. 3](#F3){ref-type="fig"}), which might be due to the reduced O~2~ deficit. It is well known that \[Lac^−^\]~p~ is determined by the balance between lactate production and consumption rates, and that \[Lac^−^\]~p~ starts to increase when the production rate exceeds the consumption rate ([@B7]). However, in the present study, it remains unknown whether the reduced \[Lac^−^\]~p~ during the graded cycling was caused by reduced lactate production rate, enhanced consumption rate, or a combination of the two due to enhanced aerobic capacity.

Another possible mechanism underlying the reduced \[Lac^−^\]~p~ in the ALA+SFC trial was a reduction in sympathetic nervous activity, the activation of which is known to stimulate glycolysis in active muscles ([@B20]) and to limit blood flow to these muscles by suppressing vasodilation due to local metabolites released by the muscles ([@B25]). However, this is implausible because we found no significant differences in the HR and BP responses during the graded cycling test between trials. These results suggest that the enhanced aerobic capacity decreased \[Lac^−^\]~p~ during the graded cycling test, which might also contribute to the prolonged time to exhaustion for the ALA+SFC trial in the present study ([Table 1](#T1){ref-type="table"}).

V̇[co]{.smallcaps}~2~ and V̇[e]{.smallcaps} during the Graded Cycling Test {#sec3-3}
------------------------------------------------------------------------

As demonstrated in [Fig. 2](#F2){ref-type="fig"}, the increase in V̇[co]{.smallcaps}~2~ was significantly reduced by a similar degree as V̇[o]{.smallcaps}~2~ at every workload during the graded cycling test in the ALA+SFC trial, with a similar V̇[e]{.smallcaps} response to V̇[co]{.smallcaps}~2~; however, we found no significant differences in the gas exchange threshold before vs. after the ALA+SFC intake period. These results suggest that the attenuated increase in V̇[co]{.smallcaps}~2~ for the ALA+SFC trial was caused not by lower respiratory compensation for metabolic acidosis due to the attenuated increase in \[Lac^−^\]~p~, but by a lower CO~2~ production rate due to a lower [o]{.smallcaps}~2~ consumption rate at every workload.

Taken together, these results from laboratory-based experiments suggest that ALA recovers the age-associated decrease in exercise efficiency; however, it remains unknown whether ALA also improves training achievement in the field.

Training Achievement during the Supplement Intake Period {#sec3-4}
--------------------------------------------------------

Until this study, no studies have examined how nutritional supplements affected achievement of home-based walking training. This might be because there is no system that can precisely monitor exercise intensity during home-based walking training, although a higher intensity of aerobic exercise (\>50% V̇[o]{.smallcaps}~2\ peak~) has been recommended in recent guidelines to increase V̇[o]{.smallcaps}~2\ peak~ in older people ([@B1]). To alleviate this difficulty, we recently developed a home-based walking training system that comprises IWT that is programmed according to the individual V̇[o]{.smallcaps}~2\ peak~ and an information technology network system that tracks the exercise intensity and energy expenditure during training ([@B34], [@B36], [@B52]). Using this system, in the present study, we found that training days, impulse, and time at fast walking during the supplement intake period significantly increased in the ALA+SFC trial compared with the CNT trial, as summarized in [Fig. 5](#F5){ref-type="fig"}. The precise mechanisms for this remained unclear. However, in the ALA+SFC trial, V̇[o]{.smallcaps}~2~ and V̇[co]{.smallcaps}~2~ were saved at every workload ([Fig. 2](#F2){ref-type="fig"}), the increase in \[Lac^−^\]~p~ was significantly attenuated ([Fig. 3](#F3){ref-type="fig"}), and the time to exhaustion was prolonged, and the subjective feeling of fast walking might thus be improved due to reduced panting and muscle pain, ultimately resulting in increases in impulse and time at fast walking in the trial ([Fig. 5](#F5){ref-type="fig"}). This is consistent with a recent study showing that higher muscle mitochondrial efficiency was associated with a faster preferred walking speed in older adults ([@B9]).

Moreover, as shown in [Fig. 6](#F6){ref-type="fig"}, the training achievement in the ALA+SFC trial started to increase after the 3rd day of supplement intake, which suggests that at least 3 days are required to attain the effects of ALA+SFC intake in the protocol used in the present study. Although this response seems slow, Mingone et al. ([@B28]) reported that, in an organ culture of bovine pulmonary arteries with ALA and iron ion, a significant increase in heme content was observed after 24 h of incubation. They also examined the time-dependent effects of organ culture with ALA on generating protoporphyrin IX, the heme precursor, and reported that at least a 24-h culture period was required to detect the ALA-induced effect. Therefore, in the present study, if the increased training achievement was caused by ALA+SFC-induced increases in heme content and subsequent improvements of mitochondrial function, it seems reasonable to observe these changes after the 3rd day of supplement intake.

Alternatively, the increased training achievement in the ALA+SFC trial might be related to enhanced central mechanisms. ALA administration to rats reportedly induced increased levels of tryptophan and serotonin in the forebrain ([@B12]), which might enhance the melatonin concentration in the pineal gland and improve the circadian rhythm in older people ([@B41]). Indeed, Rodriguez et al. ([@B44]) suggested that, in middle-aged and older subjects, the ingestion of ALA+SFC (50 and 57 mg/day, respectively) for 6 wk improved the quality of sleep, emotional state, and reaction to psychological stress evaluated by questionnaires. Therefore, in the present study, we could not exclude the possibility that the increased training achievement in the ALA+SFC trial was caused by enhanced central mechanisms.

Limitations {#sec3-5}
-----------

Iron intake per day in the ALA+SFC trial (supplement + dietary intake, [Tables 2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}) was three times higher than the RDA value ([@B29]). Therefore, the possible effects of iron intake on the results were not excluded; however, because subjects showed no symptoms of iron deficiency anemia in the health examination before participating in the study and because \[Hb\] did not change after ALA+SFC supplementation, it was unlikely that SFC was independently incorporated into the mitochondrial function in the ALA+SFC trial. Therefore, we surmise that the simultaneous ingestion of a mixture of ALA and iron ion is necessary to attain the results, and this interpretation is consistent with several other studies assessing the effects of ALA combined with the iron ion ([@B21], [@B28], [@B31], [@B35], [@B43]).

We employed no sedentary groups in the present study. Because this is the first study to examine whether ALA+SFC supplementation improved exercise efficiency and facilitated training achievement in older people, we started with subjects who were expected to have high and chronic heme demand to compensate for insufficient ATP production during daily IWT. Therefore, it remains unknown whether supplementation would increase the O~2~ utilization efficiency in sedentary subjects.

We used a cycle ergometer to evaluate exercise efficiency, while exercise format in the field experiment was walking. We used this approach because it is more challenging to accurately measure external work done during walking. However, we believe that the improvement in efficiency during cycling observed in the present study is likely to provide some insight into the increased IWT achievement.

In conclusion, the supplementation of ALA+SFC increased exercise efficiency determined as work per the total metabolic cost of exercise and improved voluntary achievement of IWT in older women who had performed habitual training before this study. Because higher training achievement is associated with greater improvements in physical fitness and risk factors for lifestyle-related disease ([@B27]), this regimen would be useful to help older women continue habitual exercise training and thus improve their health.
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